Wolverine Trading’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Wolverine Trading’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,874	Closed	-$274K	–	4252
2016 Q4	$274K	Buy	+6,874	New	+$294K	﹤0.01%	3364

Other funds holding BIB

CCWM

Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wolverine Trading's BIB Position: Q1 2017 in Review

Wolverine Trading sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2017, closing a stake of 6,874 shares — an estimated $274K sold.

Wolverine Trading first reported a position in BIB in Q4 2016 and held it in 1 quarter. The position peaked at $274K in Q4 2016. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2017.

Wolverine Trading reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2017 after selling out during the quarter.
Wolverine Trading sold 6,874 ProShares Ultra NASDAQ Biotechnology shares in Q1 2017, an estimated $274K.
Wolverine Trading first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2016 and held it in 1 quarter.
Wolverine Trading's ProShares Ultra NASDAQ Biotechnology position peaked at $274K in Q4 2016.
28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2017.

Based on Wolverine Trading's 13F filing for Q1 2017, filed 15 May 2017.